Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 43 member 2 (SLC43A2), also known as Large Neutral Amino Acids Transporter 4 (LAT4), is a sodium-independent uniporter that facilitates the transport of essential neutral amino acids like leucine and phenylalanine across the plasma membrane (UniProt Q8N370). It is a member of the solute carrier family 43 and is primarily expressed in the basolateral membrane of epithelial cells in the kidney, small intestine, and placenta (PubMed: 11598138). The biological function of SLC43A2 is critical for nutrient sensing, as it helps regulate the intracellular concentration of leucine, which in turn activates the mTORC1 signaling pathway to promote cell growth (PubMed: 26439179). In the context of disease, SLC43A2 is frequently overexpressed in various cancers, where it supports the high metabolic demands and rapid proliferation of tumor cells (PubMed: 30217964). Because of its role in tumor metabolism, SLC43A2 is considered a promising therapeutic target for metabolic reprogramming in oncology. While there are currently no FDA-approved drugs specifically targeting this molecule, experimental approaches such as RNA interference (targeting SLC43A2 mRNA) and small molecule inhibitors like BCH have shown potential in preclinical studies. Therapeutic challenges include the potential for systemic toxicity, particularly regarding placental nutrient transfer and renal amino acid reabsorption. Monitoring SLC43A2 mRNA or protein expression levels can serve as a biomarker for identifying patients who may benefit from such targeted therapies.
Competitive inhibition of amino acid transport or RNA interference-mediated degradation of mRNA transcripts to reduce protein expression.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 43 member 2 (LAT4) (SLC43A2).